Medtronic - MDT Stock Forecast, Price & News

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 1 sell rating, 16 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MDT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDT, but not buy additional shares or sell existing shares.
View MDT analyst ratings or view top-rated stocks.

23 brokers have issued 12-month target prices for Medtronic's stock. Their MDT share price forecasts range from $80.00 to $135.00. On average, they anticipate the company's share price to reach $97.79 in the next twelve months. This suggests a possible upside of 23.6% from the stock's current price.
View analysts price targets for MDT or view top-rated stocks among Wall Street analysts.

Medtronic's stock was trading at $103.45 at the beginning of 2022. Since then, MDT stock has decreased by 23.5% and is now trading at $79.12.
View the best growth stocks for 2022 here.

Medtronic saw a increase in short interest in October. As of October 31st, there was short interest totaling 9,630,000 shares, an increase of 19.8% from the October 15th total of 8,040,000 shares. Based on an average daily trading volume, of 6,040,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.7% of the shares of the stock are short sold.
View Medtronic's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our MDT earnings forecast.

Medtronic plc (NYSE:MDT) issued its earnings results on Tuesday, November, 22nd. The medical technology company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.02. The medical technology company earned $7.59 billion during the quarter, compared to analysts' expectations of $7.70 billion. Medtronic had a net margin of 14.03% and a trailing twelve-month return on equity of 13.52%. Medtronic's revenue was down 3.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.32 EPS.
Read the conference call transcript.

Medtronic declared a quarterly dividend on Thursday, August 18th. Stockholders of record on Friday, September 23rd will be given a dividend of $0.68 per share on Friday, October 14th. This represents a $2.72 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend is Thursday, September 22nd.
Read our dividend analysis for MDT.

Medtronic (NYSE:MDT) pays an annual dividend of $2.72 per share and currently has a dividend yield of 3.44%. The company has been increasing its dividend for 45 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 84.47%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MDT will have a dividend payout ratio of 49.19% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MDT.

Medtronic issued an update on its FY23 earnings guidance on Tuesday, November, 22nd. The company provided earnings per share guidance of $5.25-5.30 for the period, compared to the consensus EPS estimate of $5.53.

1,925 employees have rated Medtronic Chief Executive Officer Omar S. Ishrak on Glassdoor.com. Omar S. Ishrak has an approval rating of 92% among the company's employees. This puts Omar S. Ishrak in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), Home Depot (HD) and Walmart (WMT).

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Medtronic's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.32%), BlackRock Inc. (8.73%), State Street Corp (4.44%), Massachusetts Financial Services Co. MA (2.57%), Bank of New York Mellon Corp (1.46%) and Lazard Asset Management LLC (1.05%). Insiders that own company stock include Bradley E Lerman, Brett A Wall, Brett A Wall, Carol A Surface, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, John R Liddicoat, Karen L Parkhill, Karen L Parkhill, Omar Ishrak, Richard H Anderson, Richard H Anderson, Robert John White and Sean Salmon.
View institutional ownership trends.

Shares of MDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDT stock can currently be purchased for approximately $79.12.

Medtronic (NYSE:MDT) has a market capitalization of $105.16 billion and generates $31.69 billion in revenue each year. The medical technology company earns $5.04 billion in net income (profit) each year or $3.22 on an earnings per share basis.

The company employs 95,000 workers across the globe.

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The official website for the company is www.medtronic.com. The medical technology company can be reached via phone at (531) 438-1700, via email at investor.relations@medtronic.com, or via fax at 763-514-4879.